Legend Biotech Corporation
Legend Biotech has emerged as one of the most successful cell therapy companies globally, with its BCMA-targeted CAR-T therapy CARVYKTI achieving approximately $1.9 billion in global end-user sales during 2025. The company recorded $627 million in recognized revenue and has treated over 10,000 patients across 18 markets worldwide. A collaboration with Johnson & Johnson has enabled rapid global commercial expansion and manufacturing capacity buildout.
Strengths: CARVYKTI's exceptional clinical data with high complete response rates; successful expansion into earlier multiple myeloma treatment lines; state-of-the-art manufacturing facility in Raritan, New Jersey (10,000-patient annual capacity); cash reserves of $835 million supporting R&D and expansion; 100% pure-play CGT focus ensuring undivided strategic attention.
Weaknesses: Single-product dependency on CARVYKTI with limited pipeline diversification; foreign exchange exposure evidenced by $57.3M unrealized FX losses; still-nascent commercial infrastructure in emerging markets compared to big pharma peers; reliance on Janssen partnership for certain manufacturing and distribution capabilities.Read More ▼Show Less ▲
Strengths: CARVYKTI's exceptional clinical data with high complete response rates; successful expansion into earlier multiple myeloma treatment lines; state-of-the-art manufacturing facility in Raritan, New Jersey (10,000-patient annual capacity); cash reserves of $835 million supporting R&D and expansion; 100% pure-play CGT focus ensuring undivided strategic attention.
Weaknesses: Single-product dependency on CARVYKTI with limited pipeline diversification; foreign exchange exposure evidenced by $57.3M unrealized FX losses; still-nascent commercial infrastructure in emerging markets compared to big pharma peers; reliance on Janssen partnership for certain manufacturing and distribution capabilities.
Listed market data
LEGN · NASDAQ · weeklyHistory →- Market cap
- $3.6 B
- Share price
- USD 18.48
- 1Y change
- -42.2%
- Recent change
- +2.0%
- IPO price
- -47.9%
- Revenue (TTM)
- $1.3 B
10-22 → 10-23
USD 23.00 · from 6/05/2020
Financial history
Full market history- 2026-10USD 18.48$3.6 B-7.1%
- 2026-09USD 19.89$3.7 B-4.3%
- 2026-08USD 20.78$3.9 B+12.0%
- 2026-07USD 18.55$3.5 B-35.8%
- 2026-06USD 28.88$5.4 B+6.3%
- 2026-05USD 27.16$5.1 B+15.5%
- 2026-04USD 23.52$4.4 B+30.0%
- 2026-03USD 18.09$3.4 B-4.8%
- 2026-02USD 19.00$3.5 B+8.6%
- 2026-01USD 17.50$3.3 B-19.5%
- 2025-12USD 21.74$4.1 B-21.5%
- 2025-11USD 27.71$5.2 B—
In the press
All coverage →5 latest headlines1- JPMorgan cuts target for Legend Biotech stock to USD 33 - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Legend Biotech Corporation (LEGN) Options Chain - Yahoo! Finance Canadaca.finance.yahoo.com2026-10-18
- Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History - Yahoo! Finance Canadaca.finance.yahoo.com2026-10-16
- Legend Biotech Receives FDA Clearance for In Vivo CAR-T Therapy Trial - marketscreener.comwww.marketscreener.com2026-10-15
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapyfinance.yahoo.com2026-10-15
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $1 B | −$297 M |
| 2024 | $627 M | −$177 M |
| 2023 | $285 M | −$518 M |
| 2022 | $117 M | −$446 M |
| 2021 | $68.8 M | −$404 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Somerset, New Jersey, United States
Founded
2014
Employees
1,500
Revenue
$627M (recognized) / $1.9B (end-user sales, 2025)
Market cap
$3.6 B
Factories
Raritan NJ mega-plant (10,000-patient capacity), Ghent BE (planned)
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: LEGN , Legend Biotech FY2025 Financial Results | Legend Biotech Q1 2026 Results | Legend Biotech — Wikipedia | Legend Biotech Official Website